Polymarket
US grants license for new nuclear reactor in 2026?
US grants license for new nuclear reactor in 2026?
ORA · NYSE
buy · 10 ratings
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| July 16, 2026 | Barclays | Maintains | Overweight | $127.00 |
| May 18, 2026 | Piper Sandler | Maintains | Overweight | $142.00 |
| May 8, 2026 | UBS | Maintains | Buy | $152.00 |
| May 8, 2026 | JP Morgan | Maintains | Neutral | $123.00 |
| May 8, 2026 | Barclays | Maintains | Overweight | $126.00 |
| April 16, 2026 | JP Morgan | Maintains | Neutral | $106.00 |
| March 3, 2026 | UBS | Maintains | Buy | $143.00 |
| March 2, 2026 | Barclays | Maintains | Overweight | $123.00 |
| February 27, 2026 | Baird | Maintains | Outperform | $130.00 |
| February 18, 2026 | Citigroup | Maintains | Neutral | $128.00 |
| February 13, 2026 | Jefferies | Downgrades | Hold | $130.00 |
| January 27, 2026 | Oppenheimer | Maintains | Outperform | $136.00 |
| January 15, 2026 | Barclays | Maintains | Overweight | $108.00 |
| January 9, 2026 | TD Cowen | Upgrades | Buy | $130.00 |
| December 18, 2025 | Piper Sandler | Maintains | Overweight | $125.00 |
| November 7, 2025 | UBS | Maintains | Buy | $135.00 |
| November 7, 2025 | Barclays | Maintains | Overweight | $118.00 |
| November 5, 2025 | JP Morgan | Maintains | Neutral | $111.00 |
| November 5, 2025 | TD Cowen | Maintains | Hold | $100.00 |
| November 5, 2025 | Roth Capital | Reiterates | Buy | $125.00 |
| October 16, 2025 | JP Morgan | Maintains | Neutral | $99.00 |
| October 7, 2025 | Jefferies | Maintains | Buy | $120.00 |
| September 17, 2025 | Piper Sandler | Upgrades | Overweight | $102.00 |
Live event probabilities associated with this company or market.
Polymarket
US grants license for new nuclear reactor in 2026?
Ormat trades at a premium valuation that is justified by its unique positioning as a reliable, carbon-free baseload geothermal power provider. Extended tax credits (PTC/ITC) through 2033, rising PPA pricing driven by data center and industrial electrification demand, and a fair value estimate of $135.45 support the current earnings multiple.
At approximately 50x earnings — far above the 22x fair ratio estimate and the 16x renewable energy industry average — Ormat's valuation looks dangerously stretched. Bernstein initiated coverage with an underperform rating and a $115 price target, reflecting concern that the premium multiple leaves little margin for error.
Ormat demonstrated strong operational momentum with Q1 2026 revenue of $403.91 million, well above analyst estimates of $349.17 million. Full-year 2026 guidance of $1.11B–$1.16B and projected annual earnings growth of 13.6% signal sustained financial strength, drawing outperform ratings from UBS ($152 target), Oppenheimer ($144), and Barclays ($127).
Despite strong headline numbers, the stock has declined roughly 22% over the past month and 8% year-to-date, suggesting the market is skeptical about whether growth can be sustained. Jefferies downgraded ORA to hold, and Citigroup maintains a hold, reflecting doubts about near-term earnings visibility.
Ormat's geothermal business model provides long-term contracted, baseload revenue that justifies heavy capital deployment. Elevated demand from technology sector customers (data centers) and industrial users is translating into premium PPA pricing, supporting margin expansion and improving the return profile of new project investments.
High capital expenditure requirements risk straining Ormat's balance sheet, particularly if U.S. regulations targeting Chinese battery components negatively impact energy storage growth. The PEG ratio of 3.84x signals the market may already be pricing in risks tied to aggressive spending outpacing earnings generation.